载脂蛋白J在大鼠颈动脉再狭窄模型中表达规律的研究

Expression Pattern of Apolipoprotein J in Rat's Model of Carotid Artery Restenosis

目的:研究载脂蛋白J(Apo J)在大鼠颈动脉球囊扩张后血管再狭窄模型中的表达规律。方法:40只Wistar大鼠随机分为两组:实验组和对照组,每组20只。采用2F Fogarty球囊导管于右侧颈总动脉进行球囊拉伤造模,术后1、2、3、4周共四个时间点,每组每个时间点5只大鼠。在各时间点,取右侧颈总动脉后,采用苏木伊红染色法(HE)观察其形态学变化,免疫组化检测Apo J蛋白表达,实时定量聚合酶链式反应(qRT-PCR)检测Apo J基因的表达水平。结果:与对照组各时间点相比,实验组在相同时间点内膜增生明显,Apo J蛋白及基因表达明显上调(P<0.05);且实验组随着损伤时间延长,内膜持续增生至第四周达到最大值,Apo J蛋白及基因表达在第3周达到高峰,第4周有所下降(P<0.05)。结论:Apo J可能与血管损伤及损伤后内膜增生密切相关,血管中高表达的Apo J主要来源于损伤组织局部的血管平滑肌细胞(VSMC)合成,推测它可能是损伤后的一种代偿,通过抑制VSMC的增值和迁移的活性对再狭窄起保护作用。为寻找新的经皮冠状动脉介入治疗术后血管再狭窄的干预提供新的靶点。

Objective： To study the expression pattern of apolipoprotein J （Apo J） in rat＇s model of vascular restenosis after cartid balloon dilation. Methods： A total of 40 Wistar rats were randomly divided into 2 groups： Experimental group, the rat＇s model of carotid artery injury was established by 2 F Fogarty balloon catheter scratching in right carotid artery and Control group, the rats received sham operation without catheter scratching. n=20 in each group. Right carotid artery tissue was taken at 1, 2, 3, 4 weeks after the operation respectively and 5 rats were used for each time point. The morphological changes were measured by HE staining, protein and gene expressions of Apo J were examined by immunohistochemistry and qRT-PCR. Results： Compared with Control group, at each time point Experimental group had obvious intimal hyperplasia and up-regulated protein and gene expressions of Apo J, P〈0.05. In Experimental group, with prolonged time of injury, consistent endometrial hyperplasia was observed and it reached the maximum at 4 weeks after operation; the peak protein and gene expressions of Apo J was found at 3 weeks after operation, then decreased at certain point at 4 weeks after operation, P〈0.05. Conclusion： Apo J might be closely related to intimal hyperplasia after vascular injury, high expression of vascular Apo J was mainly derived from vascular smooth muscle cell synthesis, it could be a kind of compensation with protective role and might be used as a new biological target for treating vascular retenosis after percutaneous coronary intervention.